639 related articles for article (PubMed ID: 33585244)
1. Pan-Cancer Molecular Characterization of m
Zhu J; Xiao J; Wang M; Hu D
Front Oncol; 2020; 10():618374. PubMed ID: 33585244
[TBL] [Abstract][Full Text] [Related]
2. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
3. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
4. Pan-Cancer Analysis Revealed
Liu J; Wang Y; Yin J; Yang Y; Geng R; Zhong Z; Ni S; Liu W; Du M; Yu H; Bai J
J Oncol; 2022; 2022():3477148. PubMed ID: 35069733
[TBL] [Abstract][Full Text] [Related]
5. Identifies microtubule-binding protein
Wang W; Zhang J; Wang Y; Xu Y; Zhang S
Comput Struct Biotechnol J; 2022; 20():3322-3335. PubMed ID: 35832625
[TBL] [Abstract][Full Text] [Related]
6. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract][Full Text] [Related]
7. The molecular feature of macrophages in tumor immune microenvironment of glioma patients.
Zhang H; Luo YB; Wu W; Zhang L; Wang Z; Dai Z; Feng S; Cao H; Cheng Q; Liu Z
Comput Struct Biotechnol J; 2021; 19():4603-4618. PubMed ID: 34471502
[TBL] [Abstract][Full Text] [Related]
8. HHLA2 Used as a Potential Prognostic and Immunological Biomarker and Correlated with Tumor Microenvironment in Pan-Cancer.
Yang Z; Xu D; Ye X; Lin X; Zhang M; Su Y; Xie Q; Ni W
Biomed Res Int; 2022; 2022():3924400. PubMed ID: 35252444
[TBL] [Abstract][Full Text] [Related]
9. The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Chang S; Yim S; Park H
Exp Mol Med; 2019 Jun; 51(6):1-17. PubMed ID: 31221981
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive analysis of the novel omicron receptor AXL in cancers.
Zhang WN; Li XP; Wang PF; Zhu L; Xiao XH; Dai YJ
Comput Struct Biotechnol J; 2022; 20():3304-3312. PubMed ID: 35782741
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive analysis of tumor necrosis factor-α-inducible protein 8-like 2 (TIPE2): A potential novel pan-cancer immune checkpoint.
Bai KH; Zhang YY; Li XP; Tian XP; Pan MM; Wang DW; Dai YJ
Comput Struct Biotechnol J; 2022; 20():5226-5234. PubMed ID: 36187930
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
[TBL] [Abstract][Full Text] [Related]
13. Role of CD47 in tumor immunity: a potential target for combination therapy.
Huang J; Liu F; Li C; Liang X; Li C; Liu Y; Yi Z; Zhang L; Fu S; Zeng Y
Sci Rep; 2022 Jun; 12(1):9803. PubMed ID: 35697717
[TBL] [Abstract][Full Text] [Related]
14. CXCL11 Correlates with Immune Infiltration and Impacts Patient Immunotherapy Efficacy: A Pan-Cancer Analysis.
Li Y; Han S; Wu B; Zhong C; Shi Y; Lv C; Fu L; Zhang Y; Lang Q; Liang Z; Yu Y; Tian Y
Front Immunol; 2022; 13():951247. PubMed ID: 35935945
[TBL] [Abstract][Full Text] [Related]
15. Pan-Cancer Analysis of PDIA3: Identifying It as a Potential Biomarker for Tumor Prognosis and Immunotherapy.
Zhang J; Wang K; Hainisayimu T; Li H
Oxid Med Cell Longev; 2022; 2022():9614819. PubMed ID: 36046686
[TBL] [Abstract][Full Text] [Related]
16. KCNN4 is a potential prognostic marker and critical factor affecting the immune status of the tumor microenvironment in kidney renal clear cell carcinoma.
Chen S; Wang C; Su X; Dai X; Li S; Mo Z
Transl Androl Urol; 2021 Jun; 10(6):2454-2470. PubMed ID: 34295732
[TBL] [Abstract][Full Text] [Related]
17. Pan-Cancer Integrated Analysis Identification of SASH3, a Potential Biomarker That Inhibits Lung Adenocarcinoma Progression.
Chen X; Yuan Y; Ren W; Zhou F; Huang X; Pu J; Niu X; Jiang X
Front Oncol; 2022; 12():927988. PubMed ID: 35756681
[TBL] [Abstract][Full Text] [Related]
18. A pan-cancer analysis of the role of
Ding G; Ma T; Zhang K; Chen G; Shen J; Zhang S; Li K; Zhao C; Wang F; Sun J; Wang J
Biotechnol Genet Eng Rev; 2023 Mar; ():1-16. PubMed ID: 36971139
[TBL] [Abstract][Full Text] [Related]
19. Immune-Stromal Score Signature: Novel Prognostic Tool of the Tumor Microenvironment in Lung Adenocarcinoma.
Qi X; Qi C; Qin B; Kang X; Hu Y; Han W
Front Oncol; 2020; 10():541330. PubMed ID: 33072571
[No Abstract] [Full Text] [Related]
20. A comprehensive pan-cancer analysis of the expression characteristics, prognostic value, and immune characteristics of
Fei L; Lu Z; Xu Y; Hou G
Front Genet; 2022; 13():920897. PubMed ID: 36035140
[No Abstract] [Full Text] [Related]
[Next] [New Search]
